[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567049":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":30,"responsibleParty":48,"collaborators":20,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":20,"eligibilityCriteria":56,"healthyVolunteers":53,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":20,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":74,"whyStopped":20,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Xuanwu Hospital, Beijing","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"EC-DBS group","EXPERIMENTAL","participants will undergo EC-DBS ON with the individual stimulation parameters determined in the parameter determination period, then continue to receive stimulation for the remainder of the study.",[13],"Device: EC-DBS ON",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","EC-DBS ON","The surgical intervention named deep brain stimulation is a well-established neurosurgical treatment for drug-resistant epilepsy.The targets used in this study are extreme capsule.The devices used for intervention have been approved by Chinese National Medical Products Administration (CFDA). The postoperative drug dosage adjustment depends on the efficacy of DBS and the judgment of the epilepsy specialist.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Liankun Ren, MD","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","+86 13681576621","renlk2022@outlook.com",[31],{"facility":32,"status":20,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Xuanwu Hospital,Capital Medical University","Beijing","Beijing Municipality","100053","China","CN",{"type":39,"coordinates":40},"Point",[41,42],116.39723,39.9075,{"lat":42,"lon":41},[45,46],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},{"name":47,"role":24,"phone":20,"phoneExt":20,"email":20},"Liankun Ren",{"type":24,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Liankun_Ren","Professor","100567049","extreme-capsule-electrical-stimulation-for-drug-resistant-focal-epilepsy-100567049",false,"NCT06663124","Extreme Capsule Electrical Stimulation for Drug-resistant Focal Epilepsy","Inclusion Criteria:\n\n* Participants are between the ages of 14 -65 years of age\n* Diagnosis of drug-resistant epilepsy follows the standard of resistance to regular medication treatment for at least two years. Comprehensive preoperative epilepsy assessment, combined with individualized fiber tracking, is used to determine whether the epileptogenic zone is located in cortex regions structurally connected to the extreme capsule.\n* Persistence of disabling seizures at least 3 times per month or greater,\n* Informed consent signed.\n\nExclusion Criteria:\n\n* Structural alterations are present in the extreme capsule.\n* Diagnosed with generalized or hereditary epilepsy with ion channel gene mutations;\n* Psychogenic non-epileptic seizures within 12 months;\n* Presence of implanted electrical stimulation medical device anywhere in the body (e.g., pacemaker, spinal cord stimulator, responsive neurostimulation) or any metallic implants in the head (e.g., aneurysm clips, cochlear implants). Note: Vagal nerve stimulators are allowed if the parameter remains stable for at least 3 months prior to the screening visit;\n* Risk factors that would put the participant at risk for intraoperative or postoperative bleeding. (e.g., coagulation abnormalities, etc.) or the need for chronic anticoagulation or antiplatelet aggregation medications;\n* IQ \\\u003C 55 or severe cognitive dysfunction, unable to complete the study;\n* Diagnosed with a progressive neurological disorder (including progressive Rasmussen's encephalitis, etc.);\n* Diagnosed with a severe neuropsychiatric disorder such as dementia, major depression (admission to a psychiatric specialty\u002Fhospital within 5 years or any suicidal or self-injurious tendencies), schizophrenia, or neurodegenerative disorders;\n* Diagnosed with other serious physical disorders, internal diseases or severe abnormalities in liver or kidney function;\n* Pregnant, or planning to pregnant within 2 years;\n* Participation in another clinical study within 3 months;\n* Not suitable for enrollment as assessed by the multidisciplinary team of the center.","ALL","14 Years","65 Years",{"count":61,"type":62},10,"ESTIMATED","INTERVENTIONAL",[65],"NA","Evaluation of the Efficacy and Safety of Deep Brain Stimulation of the Extreme Capsule (EC) for the Treatment of Drug-Resistant Epilepsy",[68],"Epilepsy, Drug Resistant",[70,71,72,73],"Extreme capsule","Deep Brain Stimulation","Drug Resistant Epilepsy","Focal Epilepsy","NOT_YET_RECRUITING","2024-10-27",{"date":77,"type":78},"2024-10-29","ACTUAL",{"date":80,"type":62},"2024-11-01",{"date":82,"type":62},"2026-11-01",{"name":5,"class":6},1]